Skip to main content

Table 1 Patient characteristics of metastatic non-small cell lung cancer (NSCLC) patients treated with nivolumab in the randomized controlled trial (RCT) and real-world

From: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

 

Trial patients

Real-world patients

P-value

n

292

141

 

Age at diagnosis in years; median (range)

61 (37-84)

64 (44-80)

0.003

Age in categories; n (%)

  

0.182

  < 70 years

241 (82.5)

108 (76.6)

 

  ≥ 70 years

51 (71.5)

33 (23.4)

 

Gender; n (%)

  

0.962

 Male

151 (51.7)

74 (52.5)

 

 Female

141 (48.3)

67 (47.5)

 

Stage; n (%)

  

0.003

 IIIB

20 (6.8)

0

 

 IV

272 (93.2)

141 (100)

 

ECOG PS; n (%)

  

< 0.001

 0

84 (28.8)

44 (31.2)

 

 1

208 (71.2)

90 (63.8)

 

 2

0

7 (5.0)

 

Presence of brain metastases; n (%)

  

0.114

 Yes

34 (11.6)

25 (17.7)

 

 No

258 (88.4)

116 (82.3)

 

Histology tumor; n (%)

  

0.006

 Adenocarcinoma

270 (92.5)

130 (92.2)

 

 Large cell carcinoma

7 (2.4)

8 (5.7)

 

 Adenosquamous

3 (1.0)

0

 

 Other

11 (3.8)

0

 

 Not otherwise specified (NOS)

0

3 (2.1)

 

PD-L1 expression; n (%)

  

< 0.001

  < 1%

108 (37.0)

33 (23.4)

 

 1-49%

57 (19.5)

29 (20.6)

 

  > 50%

66 (22.6)

10 (7.1)

 

 Unknown

61 (20.9)

69 (48.9)

 

Subsequent systemic therapy; n (%)

  

0.006

 Yes

124 (42.5)

40 (28.4)

 

 No

168 (57.5)

101 (71.6)